Healthcare
Live Price
Offline$52.96
-1.38% today
1Y Change
+53.31%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Royalty Pharma plc (RPRX) is a Healthcare stock with a market cap of $21.51B and listed on NASDAQ. The stock last traded around $52.96 and up 53.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of +20.7%, a dividend yield of 1.8%. What stands out right now is revenue +5.1%, EPS +20.7%, free cash flow -10.1% with operating margin 65.6% and ROIC 8.9%. The dividend is present but secondary, with a yield around 1.8%. Valuation already assumes a fairly strong business story at P/E 28.1 and price/sales 9.0. Stock Foundry combines RPRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RPRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RPRX Max Drawdown
-7.94%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RPRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.3B
+2.3% YoY
FY Net Income
$619.7M
+1346.9% YoY
Free Cash Flow
$2.0B
-5.9% YoY
Revenue Growth
+5.1%
EPS Growth
+20.7%
Gross Margin
100.0%
Net Margin
32.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.4B | 2.3B | 2.4B | 2.2B | 2.3B |
| Gross Profit | 2.4B | 2.3B | 2.4B | 2.2B | 2.3B |
| Operating Income | 1.6B | 1.3B | 1.5B | 307M | 1.4B |
| EBITDA | 1.6B | 1.6B | 1.9B | 424M | 1.4B |
| Net Income | 771M | 859M | 1.1B | 43M | 620M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 619M | 929M | 477M | 1.7B | 1.5B |
| Total Assets | 19.6B | 18.2B | 16.4B | 16.8B | 17.5B |
| Total Liabilities | 9.9B | 7.9B | 6.3B | 7.3B | 7.3B |
| Shareholder Equity | 6.5B | 6.9B | 6.5B | 5.6B | 5.8B |
| Total Debt | 9.0B | 7.6B | 6.1B | 7.1B | 7.1B |
| Net Debt | 8.3B | 6.7B | 5.7B | 5.4B | 5.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.0B
-5.9% YoY
Capital Expenditures
0
Free Cash Flow
2.0B
-5.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
65.6%
Net Margin
32.4%
ROE
11.9%
Debt / Equity
1.38x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.